Acral Lentiginous Melanoma. Part I. Epidemiology, Etiology, Clinical Presentation, and Diagnosis
- PMID: 39793708
- DOI: 10.1016/j.jaad.2024.10.124
Acral Lentiginous Melanoma. Part I. Epidemiology, Etiology, Clinical Presentation, and Diagnosis
Abstract
This review article focuses on acral lentiginous melanoma (ALM), a rare cutaneous malignancy and the least common subtype of cutaneous malignant melanoma (CMM). ALM exhibits distinct characteristics, such as low overall mutation rates and increased chromosomal alterations. It is associated with worse prognosis, more advanced disease, and lower survival rates compared to other CMM subtypes. The incidence of ALM varies globally, with higher rates in non-white populations, particularly affecting Black, Hispanic, and Asian individuals. Racial disparities may be attributed to a lack of awareness, biological/genetic differences, cultural values, and socioeconomic status. The etiology of ALM remains unknown, but studies suggest a limited impact of UV radiation, potential links to trauma and stress, and a unique tumor immune microenvironment. Diagnostic challenges include varied clinical presentations, with specific biopsy techniques recommended. Clinical research on ALM lacks representation from diverse populations, ultimately limiting its translatability. Understanding the molecular landscape and clinical aspects of ALM will be crucial for improved diagnosis, treatment, and addressing health disparities. LEARNING OBJECTIVES: After completing this learning activity, participants should be able to discuss the epidemiology, etiology, mutational landscape, tumor microenvironment, and clinical presentation of acral lentiginous melanoma (ALM). Moreover, participants should also be able to describe the important racial disparities observed in ALM.
Keywords: acral lentiginous melanoma; clinical; cutaneous oncology; epidemiology; melanoma; mutational landscape; skin of color; tumor immune microenvironment.
Copyright © 2025. Published by Elsevier Inc.
Similar articles
-
Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.J Surg Res. 2020 Jul;251:329-339. doi: 10.1016/j.jss.2020.02.010. Epub 2020 Mar 21. J Surg Res. 2020. PMID: 32208196
-
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.Arch Dermatol. 2009 Apr;145(4):427-34. doi: 10.1001/archdermatol.2008.609. Arch Dermatol. 2009. PMID: 19380664 Free PMC article.
-
Undereducation is afoot: Assessing the lack of acral lentiginous melanoma educational materials for skin of color.Pigment Cell Melanoma Res. 2023 Sep;36(5):431-438. doi: 10.1111/pcmr.13090. Epub 2023 Apr 25. Pigment Cell Melanoma Res. 2023. PMID: 37171057
-
Diagnosis and Management of Acral Lentiginous Melanoma.Curr Treat Options Oncol. 2018 Jun 27;19(8):42. doi: 10.1007/s11864-018-0560-y. Curr Treat Options Oncol. 2018. PMID: 29951919 Review.
-
Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma.Front Oncol. 2020 Dec 17;10:524700. doi: 10.3389/fonc.2020.524700. eCollection 2020. Front Oncol. 2020. PMID: 33392063 Free PMC article.
Cited by
-
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.Clin Transl Oncol. 2025 Aug 21. doi: 10.1007/s12094-025-04018-5. Online ahead of print. Clin Transl Oncol. 2025. PMID: 40841506
Publication types
LinkOut - more resources
Full Text Sources